Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Janus kinase family (JAK) is a group of non-receptor tyrosine kinases that play crucial roles in cytokine signaling and immune regulation. The family consists of four members: JAK1, JAK2, JAK3, and TYK2. They are named after the two-faced Roman god Janus, reflecting their structure with two near-identical phosphate-transferring domains: one active kinase domain (JH1) and a pseudokinase domain (JH2) that regulates activity. JAKs range from 120-140 kDa and have seven homology domains (JH1-7), including a FERM domain (JH4-JH7) that mediates association with cytokine receptors. JAKs are constitutively associated with the intracellular domains of type I and type II cytokine receptors. They function as signal transducers in the JAK-STAT pathway; upon cytokine binding to receptors, JAKs are activated, phosphorylate the receptors, and create docking sites for signaling molecules, especially STATs, ultimately driving gene transcription.
JAK inhibitors block cytokine signaling by inhibiting one or more JAK enzymes, thereby interfering with the JAK-STAT signaling pathway in lymphocytes.
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Janus kinase family (JAK).